MedTrace Logo

Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)

NCT00877903 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2026-03-11

No results posted yet for this study

Summary

The objective of the present study is to establish the safety and efficacy of Prochymal® following first acute myocardial infarction.

Conditions

Interventions

DRUG

Prochymal®

Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells

DRUG

Placebo

Intravenous infusion of excipients of Prochymal®

Sponsors & Collaborators

  • Mesoblast, Inc.

    lead INDUSTRY

Principal Investigators

  • Ken Borow, MD · Mesoblast, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-30
Primary Completion
2011-05-18
Completion
2016-03-14
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00877903 on ClinicalTrials.gov